Przemysław Dorożyński

Prof. Przemysław Dorożyński

Department of Drug Technology and Pharmaceutical Biotechnology, Warsaw Medical University, 02-091 Warszawa, Poland
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Drug Discovery Today
Verified
Journal Article
Closed access
GWGabriela Wyszogrodzka
Gabriela Wyszogrodzka
BMBartosz Marszałek
Bartosz Marszałek
BGBarbara Gil
Barbara Gil
Przemysław DorożyńskiPrzemysław Dorożyński
Przemysław Dorożyński

18 May 2018 in Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
GWGabriela Wyszogrodzka
Gabriela Wyszogrodzka
Przemysław DorożyńskiPrzemysław Dorożyński
Przemysław Dorożyński
BGBarbara Gil
Barbara Gil
WRWieslaw J. Roth
Wieslaw J. Roth
MSMaciej Strzempek
Maciej Strzempek
Piotr KulinowskiPiotr Kulinowski
Piotr Kulinowski
Purpose The purpose of the study was initial evaluation of applicability of metal organic framework (MOF) Fe-MIL-101-NH2 as a theranostic carrier of antituberculous drug in terms of its functionality, i.e. drug loading, drug dissolution, magnetic resonance imaging (MRI) contrast and cytotoxic safety. Methods Fe-MIL-101-NH2 was characterized using X-ray powder diffraction, FTIR spectrometry and scanning electron microscopy. The particle size analysis was determined using laser diffraction. Magnetic resonance relaxometry and MRI were carried out on phantoms of the MOF system suspended in polymer solution. Drug dissolution studies were conducted using Franz cells. For MOF cytotoxicity, commercially available fibroblasts L929 were cultured in Eagle’s Minimum Essential Medium supplemented with 10% fetal bovine serum. Results MOF particles were loaded with 12% of isoniazid. The particle size (3.37–6.45 μm) depended on the micronization method used. The proposed drug delivery system can also serve as the MRI contrast agent. The drug dissolution showed extended release of isoniazid. MOF particles accumulated in the L929 fibroblast cytoplasmic area, suggesting MOF release the drug inside the cells. The cytotoxicity confirmed safety of MOF system. Conclusions The application of MOF for extended release inhalable system proposes the novel strategy for delivery of standard antimycobacterial agents combined with monitoring of their distribution within the lung tissue.

17 December 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
GWGabriela Wyszogrodzka-Gaweł
Gabriela Wyszogrodzka-Gaweł
Przemysław DorożyńskiPrzemysław Dorożyński
Przemysław Dorożyński
Stefano GiovagnoliStefano Giovagnoli
Stefano Giovagnoli
WSWeronika Strzempek
Weronika Strzempek
EPEdyta Pesta
Edyta Pesta
Piotr KulinowskiPiotr Kulinowski
Piotr Kulinowski
The theranostic approach to local tuberculosis treatment allows drug delivery and imaging of the lungs for a better control and personalization of antibiotic therapy. Metal-organic framework (MOF) Fe-MIL-101-NH2 nanoparticles were loaded with isoniazid. To optimize their functionality a 23 factorial design of spray-drying with poly(lactide-co-glycolide) and leucine was employed. Powder aerodynamic properties were assessed using a twin stage impinger based on the dose emitted and the fine particle fraction. Magnetic resonance imaging (MRI) contrast capabilities were tested on porous lung tissue phantom and ex vivo rat lungs. Cell viability and uptake studies were conducted on murine macrophages RAW 246.9. The final product showed good aerodynamic properties, modified drug release, easier uptake by macrophages in relation to raw isoniazid-MOF, and MRI contrast capabilities. Starting from raw MOF, a fully functional inhalable theranostic system with a potential application in personalized tuberculosis pulmonary therapy was developed.

14 March 2022 in Materials
Verified
Journal Article
Open access
PDF file
Piotr KulinowskiPiotr Kulinowski
Piotr Kulinowski
PMPiotr Malczewski
Piotr Malczewski
MŁMarta Łaszcz
Marta Łaszcz
EBEwelina Baran
Ewelina Baran
Bartłomiej MilanowskiBartłomiej Milanowski
Bartłomiej Milanowski
Przemysław DorożyńskiPrzemysław Dorożyński
Przemysław Dorożyński
3D printing by selective laser sintering (SLS) of high-dose drug delivery systems using pure brittle crystalline active pharmaceutical ingredients (API) is possible but impractical. Currently used pharmaceutical grade excipients, including polymers, are primarily designed for powder compression, ensuring good mechanical properties. Using these excipients for SLS usually leads to poor mechanical properties of printed tablets (printlets). Composite printlets consisting of sintered carbon-stained polyamide (PA12) and metronidazole (Met) were manufactured by SLS to overcome the issue. The printlets were characterized using DSC and IR spectroscopy together with an assessment of mechanical properties. Functional properties of the printlets, i.e., drug release in USP3 and USP4 apparatus together with flotation assessment, were evaluated. The printlets contained 80 to 90% of Met (therapeutic dose ca. 600 mg), had hardness above 40 N (comparable with compressed tablets) and were of good quality with internal porous structure, which assured flotation. The thermal stability of the composite material and the identity of its constituents were confirmed. Elastic PA12 mesh maintained the shape and structure of the printlets during drug dissolution and flotation. Laser speed and the addition of an osmotic agent in low content influenced drug release virtually not changing composition of the printlet; time to release 80% of Met varied from 0.5 to 5 h. Composite printlets consisting of elastic insoluble PA12 mesh filled with high content of crystalline Met were manufactured by 3D SLS printing. Dissolution modification by the addition of an osmotic agent was demonstrated. The study shows the need to define the requirements for excipients dedicated to 3D printing and to search for appropriate materials for this purpose.

1 February 2011 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Przemysław DorożyńskiPrzemysław Dorożyński
Przemysław Dorożyński
Piotr KulinowskiPiotr Kulinowski
Piotr Kulinowski
Aleksander MendykAleksander Mendyk
Aleksander Mendyk
RJR. Jachowicz
R. Jachowicz

1 February 2012 in Drug Discovery Today
Verified
Journal Article
Closed access
Przemysław DorożyńskiPrzemysław Dorożyński
Przemysław Dorożyński
Piotr KulinowskiPiotr Kulinowski
Piotr Kulinowski
AMAnna Młynarczyk
Anna Młynarczyk
GSGreg J. Stanisz
Greg J. Stanisz